Open an account

Satellos Bioscience

MSLE · TORONTO

$6.42−$0.205 (−3.09%)TodayMarket closed ·
Prev close $6.63

About MSLE

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. The company is headquartered in Toronto, Ontario and currently employs 18 full-time employees. The company went IPO on 2006-12-01. The firm is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. The company is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.

Employees
20
Headquarters
TORONTO, Ontario
Listed
Dec 1, 2006
Sector
Health Care
Industry
Biotechnology
Website
satellos.com

MSLE key statistics

Market cap
193.49M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
69.96K
Volume
33.72K
Open price
$6.62
High today
$6.73
Low today
$6.42
52 Week high
$13.39
52 Week low
$5.30

Satellos Bioscience (MSLE) at a glance

Satellos Bioscience (MSLE) last traded at $6.42, with a market cap of 193.49M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $6.42 and $6.73. The current price is 0.0% above the day's low and 4.5% below its high.

Volume so far is 33.72K shares, below the average of 69.96K shares a day.

Over the past year Satellos Bioscience has ranged from $5.30 to $13.39, and now sits 14% of the way up that range.

Satellos Bioscience met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.56 per share against an estimate of -$0.4632.

The average analyst price target is $16.63, 159.0% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $16.63
Low
$7.82
Now
$6.42
High
$29.56

MSLE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 13.1% on average.

  1. Q3 FY24: reported -$0.4399 per share against an estimate of -$0.451
  2. Q4 FY24: reported -$0.4632 per share against an estimate of -$0.351
  3. Q1 FY25: reported -$0.3345 per share against an estimate of -$0.4278
  4. Q2 FY25: reported -$0.364 per share against an estimate of -$0.4278
  5. Q3 FY25: reported -$0.3573 per share against an estimate of -$0.3487
  6. Q4 FY25: reported -$1.60 per share against an estimate of -$0.1578
  7. Q1 FY26: reported -$0.53 per share against an estimate of -$0.4484
  8. Q2 FY26: reported -$0.56 per share against an estimate of -$0.4632

MSLE news

  • Vandana Singh

    Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence

  • Press releaseGlobe Newswire

    Satellos Reports 2025 Financial Results and Highlights Recent Company Progress

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Press releaseBusiness Wire

    Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

  • Press releaseBusiness Wire

    Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy

  • Press releaseBusiness Wire

    Satellos to Participate in Upcoming Investor Conferences

  • Press releaseBusiness Wire

    Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026

  • Press releaseBusiness Wire

    Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters' Option to Purchase Additional Shares

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.